These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9227138

  • 21. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G, Hof H, Mayser P, Mylonas I, Ruhnke M, Schaller M, Weissenbacher ER.
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [Abstract] [Full Text] [Related]

  • 22. Mechanisms and clinical significance of antifungal resistance.
    Bille J.
    Int J Antimicrob Agents; 2000 Nov; 16(3):331-3. PubMed ID: 11091057
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.
    Costa CR, de Lemos JA, Passos XS, de Araújo CR, Cohen AJ, Souza LK, Silva Mdo R.
    Mycopathologia; 2006 Jul; 162(1):45-50. PubMed ID: 16830191
    [Abstract] [Full Text] [Related]

  • 27. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents.
    Waltimo TM, Ørstavik D, Meurman JH, Samaranayake LP, Haapasalo MP.
    Oral Microbiol Immunol; 2000 Aug; 15(4):245-8. PubMed ID: 11154410
    [Abstract] [Full Text] [Related]

  • 28. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M, Caldarola G, Tacconelli E, Morace G, Posteraro B, Cauda R, Ortona L.
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Correlation between resistance testing and typing of Candida albicans--isolates from AIDS patients and chronic recurrent oral candidiasis].
    Ruhnke M, Tennagen I, Engelmann E.
    Mycoses; 1994 Oct; 37 Suppl 1():60-3. PubMed ID: 7854368
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
    Jiang L, Yong X, Li R, Peng Y, Liu W, Qin Q, Zhang L, Liu Z, Liang H, Tao R.
    J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
    [Abstract] [Full Text] [Related]

  • 37. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S, Hofmann H.
    Mycoses; 1997 Oct; 40 Suppl 1():56-63. PubMed ID: 9417515
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The impact of polyene, azole, and DNA analogue antimycotics on the cell surface hydrophobicity of Candida albicans and Candida tropicalis in HIV infection.
    Anil S, Ellepola AN, Samaranayake LP.
    Mycopathologia; 2002 Oct; 153(4):179-85. PubMed ID: 12014477
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.